Biljana Horn

Biljana Horn, M.D.

Clinical Professor

Department: MD-PEDS-HEMATOLOGY
Business Phone: (415) 215-6930
Business Email: biljana.horn@ufl.edu

About Biljana Horn

Dr. Horn, director of our Pediatric Bone Marrow Transplant and Cell Therapy Program, earned her medical degree at the University of Zagreb. She completed a pediatric residency at Case Western Reserve University, followed by a fellowship in pediatric hematology/oncology at the National Cancer Institute and another in pediatric neuro-oncology at UCSF. Her research efforts have focused on developing reduced intensity conditioning regimens for children, improving outcomes for children with brain tumors by using high-dose chemotherapy and stem cell support, reducing transplant-related mortality, reducing relapse after transplant and developing regimens for transplant of newborns with immune deficiencies. She is a member of the AAP, the Children’s Oncology Group, the American Society of Hematology, the American Society for Blood and Marrow Transplantation, the Pediatric Blood and Marrow Transplant Consortium and the Foundation for the Accreditation of Cellular Therapy.

Accomplishments

Exceptional Physician Award
2016 · UCSF Medical Center
Thrasher Research Fund Award
2011 · Thrasher Research Fund
Hellman Family Award
2003 · Hellman Foundation
Travel Award for Research in Oncology
1994 · American Association for Cancer Research

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Bone marrow transplant
  • Graft-versus-host disease
  • Leukemia
  • Leukemia – resources
  • Lymphoma – Overview
  • Non-Hodgkin lymphoma

Research Profile

Areas of Interest
  • Bone marrow transplantation
  • Chimerism
  • Complications of HSCT
  • High dose chemotherapy for brain tumors
  • Prevention of relapse following bone marrow transplantation
  • Reduced intensity conditioning
  • Veno-occlusive liver disease (VOD)

Publications

2021
Pediatric HCT in Florida (2014 -2016): A report from the FPBCC.
Pediatric transplantation. 25(5) [DOI] 10.1111/petr.13931. [PMID] 33245834.
2021
Potential Risk Factors Associated With Graft Failure of Haploidentical Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease.
Journal of pediatric hematology/oncology. 43(4):e583-e586 [DOI] 10.1097/MPH.0000000000001873. [PMID] 32604335.
2021
Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida.
Pediatric blood & cancer. 68(10) [DOI] 10.1002/pbc.29180. [PMID] 34121322.
2021
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
Transplantation and cellular therapy. 27(8):642-649 [DOI] 10.1016/j.jtct.2021.04.007. [PMID] 34304802.
2021
Stoss therapy is safe for treatment of vitamin D deficiency in pediatric patients undergoing HSCT.
Bone marrow transplantation. 56(9):2137-2143 [DOI] 10.1038/s41409-021-01294-x. [PMID] 33875811.
2020
BK virus encephalitis and end-stage renal disease in a child with hematopoietic stem cell transplantation.
Pediatric transplantation. 24(6) [DOI] 10.1111/petr.13739. [PMID] 32412694.
2020
Parvovirus B19 infection masquerading as relapsed acute lymphoblastic leukaemia following haematopoietic stem cell transplantation.
BMJ case reports. 13(8) [DOI] 10.1136/bcr-2020-235837. [PMID] 32816883.
2020
Postautologous stem cell transplantation engraftment syndrome: Improved treatment and outcomes.
Clinical transplantation. 34(3) [DOI] 10.1111/ctr.13797. [PMID] 31997402.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances. 3(12):1837-1847 [DOI] 10.1182/bloodadvances.2018028316. [PMID] 31208955.
2019
Anakinra as an agent to control hemophagocytic lymphohistiocytosis in Griscelli type 2.
Pediatric blood & cancer. 66(12) [DOI] 10.1002/pbc.27997. [PMID] 31535456.
2019
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 25(2):362-368 [DOI] 10.1016/j.bbmt.2018.09.031. [PMID] 30287390.
2019
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 25(2):e46-e54 [DOI] 10.1016/j.bbmt.2018.11.021. [PMID] 30481594.
2019
Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT.
Bone marrow transplantation. 54(5):662-673 [DOI] 10.1038/s41409-018-0340-0. [PMID] 30531954.
2018
KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses.
Journal of virology. 92(14) [DOI] 10.1128/JVI.00298-18. [PMID] 29695433.
2017
Early mixed chimerism-based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia.
Pediatric blood & cancer. 64(8) [DOI] 10.1002/pbc.26464. [PMID] 28205327.
2017
Evaluation of Pre-Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies.
Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses. 34(1):65-73 [DOI] 10.1177/1043454216631509. [PMID] 26902499.
2017
Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies.
Bone marrow transplantation. 52(7):1057-1059 [DOI] 10.1038/bmt.2017.45. [PMID] 28394367.
2017
Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.
Journal of neuro-oncology. 131(2):359-368 [DOI] 10.1007/s11060-016-2307-6. [PMID] 27778212.
2015
Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(4):729-37 [DOI] 10.1016/j.bbmt.2014.12.029. [PMID] 25644958.
2015
Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use.
Therapeutic drug monitoring. 37(2):236-45 [DOI] 10.1097/FTD.0000000000000131. [PMID] 25162216.
2014
A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
Pediatric transplantation. 18(6):609-16 [DOI] 10.1111/petr.12310. [PMID] 24977928.
2014
A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency.
Pediatric transplantation. 18(6):602-8 [DOI] 10.1111/petr.12309. [PMID] 24977650.
2014
Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20(2):229-35 [DOI] 10.1016/j.bbmt.2013.11.001. [PMID] 24216185.
2014
SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID.
Blood. 123(2):281-9 [DOI] 10.1182/blood-2013-01-476432. [PMID] 24144642.
2013
131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
Pediatric blood & cancer. 60(5):879-84 [DOI] 10.1002/pbc.24351. [PMID] 23024113.
2013
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(13):1669-76 [DOI] 10.1200/JCO.2012.45.9719. [PMID] 23547077.
2013
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.
Bone marrow transplantation. 48(8):1056-64 [DOI] 10.1038/bmt.2012.284. [PMID] 23419433.
2013
Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects.
The Journal of allergy and clinical immunology. 131(5):1306-11 [DOI] 10.1016/j.jaci.2013.03.014. [PMID] 23622119.
2012
Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.
Journal of immunotherapy (Hagerstown, Md. : 1997). 35(3):293-8 [DOI] 10.1097/CJI.0b013e31824300a2. [PMID] 22421947.
2012
Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(11):1656-63 [DOI] 10.1016/j.bbmt.2012.05.006. [PMID] 22609040.
2012
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.
Bone marrow transplantation. 47(11):1455-8 [DOI] 10.1038/bmt.2012.57. [PMID] 22465977.
2012
Massage for children undergoing hematopoietic cell transplantation: a qualitative report.
Evidence-based complementary and alternative medicine : eCAM. 2012 [DOI] 10.1155/2012/792042. [PMID] 22474526.
2010
Clinical update on graft-versus-host disease in children.
Seminars in cutaneous medicine and surgery. 29(2):92-105 [DOI] 10.1016/j.sder.2010.03.010. [PMID] 20579598.
2010
Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs.
Bone marrow transplantation. 45(11):1602-6 [DOI] 10.1038/bmt.2010.31. [PMID] 20190839.
2009
Development of herpes simplex virus stomatitis during receipt of cidofovir therapy.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 49(8):e92-5 [DOI] 10.1086/605678. [PMID] 19761410.
2009
Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.
The Pediatric infectious disease journal. 28(1):65-7 [DOI] 10.1097/INF.0b013e318182026f. [PMID] 19034064.
2009
Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation.
Journal of pediatric hematology/oncology. 31(4):300-3 [DOI] 10.1097/MPH.0b013e3181914a81. [PMID] 19346887.
2008
Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.
Bone marrow transplantation. 42(2):83-91 [DOI] 10.1038/bmt.2008.89. [PMID] 18391990.
2008
Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors.
Pediatric blood & cancer. 51(2):235-40 [DOI] 10.1002/pbc.21578. [PMID] 18381756.
2008
Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 14(10):1125-1133 [DOI] 10.1016/j.bbmt.2008.07.008. [PMID] 18804042.
2006
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(3):500-6 [PMID] 16421427.
View on: PubMed
2002
Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients.
Journal of pediatric hematology/oncology. 24(9):746-50 [PMID] 12468917.
View on: PubMed

Grants

Jul 2019 ACTIVE
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID receiving TCRaB+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatr
Role: Principal Investigator
Funding: CHILDRENS HOSP LOS ANGELES via NATL INST OF HLTH
Apr 2019 ACTIVE
Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
Role: Co-Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA

Education

Fellowship
1994 · National Cancer Institute
Residency
1991 · Case Western Reserve
M.D.
1987 · University of Zagreb, Croatia

Contact Details

Phones:
Business:
(415) 215-6930
Emails: